The regulatory life sciences partner will join Hogan Lovells’ Amsterdam office on 1 July along with lawyers Bart Jong, Hein van den Bos, Paul Loeb, Ruth Franken and Frederique Reijntjes.
Schoonderbeek has experience in all areas of law relating to the pharmaceutical, biotechnology and medical device sector. She has litigation experience in regulatory matters, extensive knowledge of EC regulatory affairs and broad experience of M&A in the pharmaceutical industry and venture capital investments in the biotechnology sector.
Her appointment strengthens the firm’s global life sciences and government regulatory practices as well as its life sciences team in the Netherlands.
In a statement, Hogan Lovells co-chief executive David Harris said: “Our global platform, together with the strength of our life sciences practice, were significant elements in attracting a candidate of Carla’s calibre.”
Commenting on her new appointment, Schoonderbeek said: “Hogan Lovells provides me with a global platform to build my practice. I look forward to working with my new colleagues in the Netherlands and internationally and being part of what I believe will be the world’s leading life sciences practice.”